AtriCure Company Insiders
ATRC Stock | USD 23.17 0.56 2.48% |
AtriCure's insiders are aggressively selling. The analysis of insiders' sentiment of trading AtriCure stock suggests that all insiders are panicking at this time. AtriCure employs about 1.2 K people. The company is managed by 27 executives with a total tenure of roughly 221 years, averaging almost 8.0 years of service per executive, having 44.44 employees per reported executive.
Michael Carrel CEO CEO and President and Director |
Richard Johnston Chairman Independent Chairman of the Board |
AtriCure's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-04-01 | Justin J Noznesky | Disposed 1500 @ 30.39 | View | ||
2024-03-18 | Karl S Dahlquist | Disposed 1885 @ 32.16 | View | ||
2024-03-12 | Justin J Noznesky | Disposed 1500 @ 36.72 | View | ||
2024-03-05 | Karl S Dahlquist | Disposed 8231 @ 37.36 | View | ||
2023-11-01 | Karl S Dahlquist | Disposed 1248 @ 34.43 | View | ||
2023-07-26 | Karl S Dahlquist | Disposed 3417 @ 57.09 | View | ||
2023-06-08 | Karen Prange | Disposed 713 @ 47.89 | View | ||
2023-06-06 | Karl S Dahlquist | Disposed 1422 @ 47.03 | View | ||
2023-05-26 | Maggie Yuen | Disposed 4313 @ 47.04 | View |
Monitoring AtriCure's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
AtriCure |
AtriCure's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AtriCure's future performance. Based on our forecasts, it is anticipated that AtriCure will maintain a workforce of about 1200 employees by May 2024.AtriCure's latest congressional trading
Congressional trading in companies like AtriCure, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in AtriCure by those in governmental positions are based on the same information available to the general public.
2021-06-08 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2020-04-30 | Representative Gilbert Cisneros | Disposed Under $15K | Verify |
AtriCure Management Team Effectiveness
The company has return on total asset (ROA) of (0.0324) % which means that it has lost $0.0324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of April 29, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.06. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.As of April 29, 2024, Common Stock Shares Outstanding is expected to decline to about 24.2 M. The current year's Net Loss is expected to grow to about (39.7 M)
AtriCure Workforce Comparison
AtriCure is rated second in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 7,767. AtriCure retains roughly 1,200 in number of employees claiming about 15% of equities under Health Care industry.
AtriCure Profit Margins
The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.12) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.12.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.58 | 0.7449 |
|
|
AtriCure Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AtriCure insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.5 | 18 | 12 | 378,137 | 118,157 |
2023-12-01 | 0.5 | 1 | 2 | 98.00 | 11,248 |
2023-06-01 | 2.8 | 14 | 5 | 26,084 | 11,865 |
2023-03-01 | 1.7 | 17 | 10 | 331,011 | 107,373 |
2022-12-01 | 3.0 | 3 | 1 | 1,488 | 6,000 |
2022-09-01 | 1.0 | 1 | 1 | 15,000 | 5,191 |
2022-06-01 | 4.3333 | 13 | 3 | 46,812 | 3,485 |
2022-03-01 | 0.8125 | 13 | 16 | 169,337 | 128,297 |
2021-12-01 | 0.625 | 5 | 8 | 481.00 | 22,219 |
2021-06-01 | 1.0435 | 24 | 23 | 113,472 | 186,791 |
2021-03-01 | 0.6538 | 17 | 26 | 236,678 | 530,260 |
2020-12-01 | 0.5417 | 13 | 24 | 238,065 | 515,481 |
2020-09-01 | 0.2 | 1 | 5 | 35,310 | 26,909 |
2020-06-01 | 1.5 | 18 | 12 | 118,795 | 204,000 |
2020-03-01 | 0.4524 | 19 | 42 | 414,351 | 1,015,232 |
2019-12-01 | 1.2 | 6 | 5 | 13,704 | 45,145 |
2019-09-01 | 0.3333 | 3 | 9 | 26,954 | 120,808 |
2019-06-01 | 1.7143 | 12 | 7 | 50,223 | 73,230 |
2019-03-01 | 0.6667 | 8 | 12 | 114,434 | 215,512 |
2018-06-01 | 2.3333 | 14 | 6 | 64,792 | 29,415 |
2018-03-01 | 0.7692 | 10 | 13 | 271,177 | 171,604 |
2017-12-01 | 1.6667 | 5 | 3 | 4,946 | 5,400 |
2017-09-01 | 0.8 | 4 | 5 | 155,000 | 48,000 |
2017-06-01 | 2.0 | 22 | 11 | 149,151 | 166,224 |
2017-03-01 | 0.6154 | 8 | 13 | 338,938 | 79,448 |
2016-12-01 | 0.5833 | 7 | 12 | 61,783 | 64,823 |
2016-09-01 | 0.5 | 2 | 4 | 18,000 | 29,000 |
2016-06-01 | 7.0 | 14 | 2 | 103,752 | 10,199 |
2016-03-01 | 0.6429 | 9 | 14 | 505,000 | 120,431 |
2015-12-01 | 0.6364 | 7 | 11 | 26,225 | 59,161 |
2015-06-01 | 1.5833 | 19 | 12 | 128,198 | 87,159 |
2015-03-01 | 0.5652 | 13 | 23 | 358,288 | 195,321 |
2014-12-01 | 0.5714 | 4 | 7 | 1,718 | 39,322 |
2014-06-01 | 3.5 | 14 | 4 | 84,264 | 51,029 |
2014-03-01 | 1.4 | 21 | 15 | 729,431 | 207,577 |
2013-12-01 | 0.3333 | 3 | 9 | 3,656 | 169,056 |
2013-09-01 | 0.2727 | 3 | 11 | 60,000 | 100,000 |
2013-06-01 | 0.6471 | 11 | 17 | 83,832 | 201,012 |
2013-03-01 | 0.3529 | 6 | 17 | 155,922 | 96,405 |
2012-12-01 | 1.0556 | 19 | 18 | 699,887 | 120,020 |
2012-09-01 | 2.3 | 23 | 10 | 42,211 | 366,389 |
2012-06-01 | 0.5455 | 18 | 33 | 320,596 | 1,776,791 |
2012-03-01 | 0.5455 | 12 | 22 | 249,900 | 54,667 |
2011-12-01 | 0.3077 | 4 | 13 | 6,321 | 72,705 |
2011-06-01 | 0.92 | 23 | 25 | 216,299 | 407,775 |
2011-03-01 | 1.5208 | 73 | 48 | 700,257 | 357,773 |
2010-12-01 | 4.3333 | 39 | 9 | 167,288 | 51,021 |
2010-09-01 | 0.1111 | 1 | 9 | 3,720 | 23,126 |
2010-06-01 | 3.6667 | 11 | 3 | 78,293 | 9,844 |
2010-03-01 | 3.75 | 15 | 4 | 364,800 | 8,108 |
2009-12-01 | 1.2857 | 9 | 7 | 32,137 | 4,204 |
2009-09-01 | 17.0 | 17 | 1 | 351,252 | 10,000 |
2009-06-01 | 1.2308 | 16 | 13 | 93,283 | 112,580 |
2008-12-01 | 25.0 | 25 | 1 | 71,600 | 2,000 |
2008-06-01 | 1.5 | 42 | 28 | 262,000 | 98,343 |
2008-03-01 | 0.2222 | 2 | 9 | 53,000 | 57,667 |
2007-06-01 | 7.5 | 15 | 2 | 315,537 | 10,000 |
2007-03-01 | 0.4 | 2 | 5 | 92,104 | 217,104 |
2006-09-01 | 0.6 | 12 | 20 | 134,892 | 173,223 |
2006-06-01 | 1.75 | 7 | 4 | 170,000 | 42,565 |
2006-03-01 | 1.0 | 1 | 1 | 10,000 | 28,506 |
2005-12-01 | 1.6667 | 5 | 3 | 193,157 | 18,419 |
2005-09-01 | 0.7419 | 23 | 31 | 5,594,284 | 1,690,878 |
AtriCure Notable Stakeholders
An AtriCure stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AtriCure often face trade-offs trying to please all of them. AtriCure's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AtriCure's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Carrel | CEO and President and Director | Profile | |
Richard Johnston | Independent Chairman of the Board | Profile | |
Patricia Kennedy | Vice President General Manager - International | Profile | |
Justin Noznesky | Senior Vice President Marketing and Business Development | Profile | |
Andrew Wade | CFO, Senior Vice President | Profile | |
Salvatore Privitera | CTO | Profile | |
Andrew Lux | Sr. VP of Operations and Quality Assurance | Profile | |
Regina Groves | Independent Director | Profile | |
Scott Drake | Independent Director | Profile | |
Mark Collar | Independent Director | Profile | |
Mark Lanning | Independent Director | Profile | |
Robert White | Independent Director | Profile | |
Sven Wehrwein | Independent Director | Profile | |
Elizabeth Krell | Independent Director | Profile | |
Michael Hooven | Founder and Director | Profile | |
Karen Robards | Independent Director | Profile | |
Kristine Johnson | Independent Director | Profile | |
Deborah Yount | Chief Officer | Profile | |
JD CCEP | Chief Officer | Profile | |
CCEP CCEP | Chief Officer | Profile | |
Valerie StorchWillhaus | Vice Communications | Profile | |
Angela CPA | Chief Officer | Profile | |
Tonya SPHR | VP HR | Profile | |
Vinayak Doraiswamy | Chief Officer | Profile | |
Salvatore JD | Chief Officer | Profile | |
Douglas Seith | Chief Officer | Profile | |
Amalio MD | Ex Officer | Profile |
About AtriCure Management Performance
The success or failure of an entity such as AtriCure often depends on how effective the management is. AtriCure management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AtriCure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AtriCure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.1) | (0.10) | |
Return On Capital Employed | (0.06) | (0.06) | |
Return On Assets | (0.05) | (0.05) | |
Return On Equity | (0.07) | (0.07) |
The data published in AtriCure's official financial statements usually reflect AtriCure's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AtriCure. For example, before you start analyzing numbers published by AtriCure accountants, it's critical to develop an understanding of what AtriCure's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of AtriCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AtriCure's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AtriCure's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AtriCure. Please utilize our Beneish M Score to check the likelihood of AtriCure's management manipulating its earnings.
AtriCure Workforce Analysis
Traditionally, organizations such as AtriCure use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AtriCure within its industry.AtriCure Manpower Efficiency
Return on AtriCure Manpower
Revenue Per Employee | 332.7K | |
Revenue Per Executive | 14.8M | |
Net Loss Per Employee | 25.4K | |
Net Loss Per Executive | 1.1M | |
Working Capital Per Employee | 159.7K | |
Working Capital Per Executive | 7.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for AtriCure Stock analysis
When running AtriCure's price analysis, check to measure AtriCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AtriCure is operating at the current time. Most of AtriCure's value examination focuses on studying past and present price action to predict the probability of AtriCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AtriCure's price. Additionally, you may evaluate how the addition of AtriCure to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is AtriCure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.66) | Revenue Per Share 8.621 | Quarterly Revenue Growth 0.21 | Return On Assets (0.03) | Return On Equity (0.07) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.